Cathy Tie’s Origin Genomics targets germline gene correction under US IRB oversight
Origin Genomics launches in New York to advance germline gene correction and MRT under IRB oversight. Analyse what it means for US gene editing regulation.
Why YolTech Therapeutics’ YOLT-202 data matters for the future of gene editing in Alpha-1 Antitrypsin Deficiency
Early YOLT-202 data from YolTech Therapeutics suggests gene editing could redefine Alpha-1 Antitrypsin Deficiency treatment. Read the analysis.